Evolent Health (NYSE:EVH - Get Free Report) will release its earnings data after the market closes on Thursday, May 9th. Analysts expect Evolent Health to post earnings of $0.21 per share for the quarter. Evolent Health has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.Persons that are interested in registering for the company's earnings conference call can do so using this link.
Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, February 22nd. The technology company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.13. The company had revenue of $556.06 million during the quarter, compared to the consensus estimate of $541.87 million. Evolent Health had a positive return on equity of 6.60% and a negative net margin of 5.76%. On average, analysts expect Evolent Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Evolent Health Trading Up 0.5 %
Shares of EVH stock traded up $0.14 on Thursday, reaching $27.41. 741,297 shares of the stock were exchanged, compared to its average volume of 937,611. The stock has a market cap of $3.16 billion, a PE ratio of -21.58 and a beta of 1.57. Evolent Health has a one year low of $23.33 and a one year high of $35.83. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.01 and a quick ratio of 1.01. The stock has a 50 day moving average price of $31.60 and a 200 day moving average price of $30.27.
Analyst Ratings Changes
A number of research firms have recently weighed in on EVH. Canaccord Genuity Group dropped their target price on Evolent Health from $45.00 to $44.00 and set a "buy" rating for the company in a research report on Thursday, March 28th. William Blair reiterated an "outperform" rating on shares of Evolent Health in a report on Tuesday, January 9th. JMP Securities upped their price objective on Evolent Health from $37.00 to $38.00 and gave the company a "market outperform" rating in a report on Friday, February 23rd. Barclays began coverage on Evolent Health in a report on Wednesday, January 3rd. They issued an "overweight" rating and a $39.00 price objective for the company. Finally, JPMorgan Chase & Co. dropped their price objective on Evolent Health from $53.00 to $52.00 and set an "overweight" rating for the company in a report on Friday, March 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, Evolent Health has a consensus rating of "Moderate Buy" and an average price target of $42.70.
Get Our Latest Report on Evolent Health
Evolent Health Company Profile
(
Get Free Report)
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
Further Reading
Before you consider Evolent Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolent Health wasn't on the list.
While Evolent Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
